Pfizer Inc.
At today's price, Pfizer Inc. (PFE) is priced for -4.3% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Pfizer is essentially one business now, biopharmaceuticals at about 98% of revenue, rebuilt after the COVID windfall faded around a pipeline weighted toward oncology and, more recently, obesity. • The defining risk is the patent cliff the 10-K spells out, a wave of exclusivity losses ⟦"in 2026 through 2030 as several of our in-line products experience these expirations,"⟧ which the company estimates at roughly $17 billion of revenue impact over 2026 to 2028. • The number that decides the thesi
Is PFE overvalued? See what's priced in →
2,864 institutional managers reported holding PFE in 13F filings for the quarter ended 2026-03-31. Together they hold about 65% of the company; the top 10 hold 33%. 197 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 162.1M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (4.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PFE's share count grew 1.7% over the past five years even with $2.00B spent on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 15 years straight; the current rate is $1.72 a share annually. Cash returned over the past three years: $26.36B in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at PFE over the trailing three years: 2023: 1 buy totaling $79k; 2024: 1 buy totaling $28k; 2025: 1 buy totaling $499k. 11 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PFE's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | -2.0% | -7.8% |
| 2023-11-09 | -0.1% | -4.3% |
| 2024-02-23 | -1.5% | -8.5% |
| 2024-05-09 | +8.1% | +1.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PFE's latest 8-K filings: 2026-06-18 (items 7.01); 2026-06-18 (items 5.02, 9.01); 2026-05-05 (items 2.02, 9.01); 2026-04-27 (items 5.07); 2026-02-03 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.